Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Radiological diagnosis of hepatic tumor(s) by contrast-enhanced study~* Subjects with advanced HCC who are not eligible for surgical resection or loco-regional therapy.~* Subjects with sorafenib treatment failure due to sorafenib intolerance or radiographic PD (as per RECIST v1.1). Prior sorafenib use should be ≥ 400 mg/day for at least 14 days.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1~* Child Pugh Score ≤ 6;~* A life expectancy of at least 12 weeks or more~Exclusion Criteria:~* Subjects who have received any systemic target therapy or systemic chemotherapy other than sorafenib for the treatment of HCC.~* Subjects who have received sorafenib within 2 weeks prior to the initiation of the treatment dose, or have any sorafenib-related toxicities not yet resolved to grade 1 or baseline.~* Subjects who have undergone liver transplantation surgery.~* Major surgery within 4 weeks prior to the initiation of the treatment dose (excluding implantation of the intravenous infusion device). Percutaneous liver puncture within 2 weeks prior to the initiation of the treatment dose.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lipotecan (Type: EXPERIMENTAL): Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).